
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Gastroenterology</li><li>- <b>Publication Date:</b> 2025;169:1397–1448</li><li>- <b>Source:</b> American Gastroenterological Association (AGA)</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What genetic risk factor is associated with an increased risk of immunogenicity to TNF antagonists, where adding an immunomodulator may be beneficial?</li><li>- In the SONIC trial, what was the rate of sustained remission at 26 weeks for infliximab + azathioprine combination therapy compared to infliximab monotherapy?</li><li>- What is the recommended weekly dose of subcutaneous methotrexate for induction of remission?</li><li>- In advanced therapy-exposed patients, which two medications are classified as 'lower efficacy'?</li><li>- In a French population-based study, by how much was the risk of lymphoma higher in patients treated with TNF-antagonist monotherapy compared to unexposed patients?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Guideline Scope & Objectives</strong></summary>
            <div>
                <ul><li>- Provides evidence-based recommendations for <b>pharmacologic management</b> of adults with moderate-to-severely active Crohn's Disease (CD).</li><li>- <b>Target Audience:</b> Gastroenterologists and primary care providers.</li><li>- Intended for use in the <u>ambulatory setting</u>.</li></ul>
                
        <details>
            <summary><strong>Definition of Moderate-to-Severe CD</strong></summary>
            <div>
                <ul><li>- Characterized by moderate to severe daily <u>abdominal pain and diarrhea</u>.</li><li>- Must be coupled with <b>confirmed active intestinal inflammation</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Applicable Patient Populations</strong></summary>
            <div>
                <ul><li>- Patients with moderate-to-severe symptoms.</li><li>- Patients with mild symptoms but predictors of future complications (e.g., high inflammation burden, extensive disease).</li><li>- Patients who are <u>corticosteroid-dependent</u>.</li><li>- Patients where disease significantly impacts quality of life.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Exclusions</strong></summary>
            <div>
                <ul><li>- This guideline does <u>not</u> cover management of:</li><li>- Postoperative CD</li><li>- Perianal CD</li><li>- Internally penetrating or stricturing CD</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Overarching Considerations (Table 2)</strong></summary>
            <div>
                <ul><li>- <b>Confirm active inflammation</b> before starting advanced therapies (symptoms, biomarkers, and/or endoscopy).</li><li>- Perform <b>pretreatment workup</b>: screen for <q>Hepatitis B and Tuberculosis</q> for all advanced therapies, and <q>thiopurine methyl transferase (TPMT)</q> testing before thiopurines.</li><li>- Assess for factors increasing treatment risk: comorbidities, frailty, cardiovascular risk factors.</li><li>- Ensure vaccinations (influenza, pneumococcus, herpes zoster) are up-to-date before starting immunosuppression.</li><li>- Monitor for symptomatic response and objective markers of inflammation after therapy initiation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Use of Advanced Therapies vs. No Treatment (Recs 1 & 2)</strong></summary>
            <div>
                <ul><li>- Based on evidence from <q>45 placebo-controlled RCTs</q>.</li></ul>
                
        <details>
            <summary><strong><b>Strong Recommendation</b> (Moderate to High Certainty)</strong></summary>
            <div>
                <ul><li>- AGA <u>recommends</u> using the following over no treatment:</li><li>- <b>Infliximab</b></li><li>- <b>Adalimumab</b></li><li>- <b>Ustekinumab</b></li><li>- <b>Risankizumab</b></li><li>- <b>Mirikizumab</b></li><li>- <b>Guselkumab</b></li><li>- <b>Upadacitinib</b></li></ul>
                
        <details>
            <summary><strong>Efficacy Data</strong></summary>
            <div>
                <ul><li>- These agents met the predefined threshold of a clinically meaningful benefit (CMD) of <q><b>>10%</b></q>.</li><li>- Magnitude of benefit for inducing remission over placebo ranged from <q>119 to 353 per 1000 patients</q> treated.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Conditional Recommendation</b> (Moderate Certainty)</strong></summary>
            <div>
                <ul><li>- AGA <u>suggests</u> using the following over no treatment:</li><li>- <b>Certolizumab pegol</b></li><li>- <b>Vedolizumab</b></li></ul>
                
        <details>
            <summary><strong>Efficacy Data</strong></summary>
            <div>
                <ul><li>- These agents did <u>not</u> meet the a priori CMD threshold of >10% for inducing remission.</li><li>- Benefit per 1000 patients treated:</li><li>- Certolizumab pegol: <q>48</q></li><li>- Vedolizumab: <q>90</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- <b>Biosimilars</b> of infliximab, adalimumab, and ustekinumab are considered <u>equivalent</u> to originator drugs.</li><li>- <b>Subcutaneous formulations</b> of infliximab and vedolizumab show comparable efficacy to IV maintenance doses.</li><li>- <b>Dose escalation</b> or extended induction may be beneficial for partial responders, especially with severe disease.</li><li>- Higher maintenance doses of risankizumab, guselkumab, and upadacitinib may be preferred for patients with high inflammation or prior TNF antagonist failure.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Harms & Safety Profile</strong></summary>
            <div>
                <ul><li>- Advanced therapies are associated with risks of <b>serious infection</b> and <b>malignancies</b>.</li><li>- <b>Ustekinumab</b> was associated with a <q><u>51% lower risk</u></q> of serious infections compared to TNF antagonists.</li><li>- <b>TNF antagonists</b> are associated with an increased risk of lymphoma and melanoma.</li><li>- A French study showed the risk of lymphoma was <q><u>2.4-times higher</u></q> in patients on TNF-antagonist monotherapy vs. unexposed patients.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Positioning of Advanced Therapies</strong></summary>
            <div>
                <ul><li>- Recommendations are informed by a Network Meta-Analysis (NMA) due to a lack of head-to-head trials.</li><li>- A clinically meaningful difference (CMD) between two active therapies was set at <q><b>>5%</b></q> absolute risk difference.</li></ul>
                
        <details>
            <summary><strong><b>Advanced Therapy-Naïve Patients</b> (Rec 3)</strong></summary>
            <div>
                <ul><li>- AGA <u>suggests</u> using a <b>HIGHER</b> efficacy medication over a <b>LOWER</b> efficacy medication.</li><li>- This is a <u>conditional recommendation</u> (low to high certainty evidence).</li></ul>
                
        <details>
            <summary><strong>Higher Efficacy Medications</strong></summary>
            <div>
                <ul><li>- <b>Infliximab</b></li><li>- <b>Adalimumab</b></li><li>- <b>Vedolizumab</b></li><li>- <b>Ustekinumab</b></li><li>- <b>Risankizumab</b></li><li>- <b>Mirikizumab</b></li><li>- <b>Guselkumab</b></li></ul>
                
        <details>
            <summary><strong>Criteria for 'Higher Efficacy'</strong></summary>
            <div>
                <ul><li>- Must meet all three criteria:</li><li>- 1. Absolute efficacy difference vs lower efficacy therapies: <q>CMD ≥5%</q>.</li><li>- 2. P score in NMA vs placebo: <q>0.49–1.0</q>.</li><li>- 3. Absolute difference vs placebo in Phase 3 trials: <q>≥15%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Lower Efficacy Medications</strong></summary>
            <div>
                <ul><li>- <b>Certolizumab pegol</b></li><li>- <b>Upadacitinib</b></li></ul>
                
        <details>
            <summary><strong>Note on Upadacitinib</strong></summary>
            <div>
                <ul><li>- Lower efficacy in biologic-naïve patients was noteworthy.</li><li>- Efficacy may be lower in <u>ileal CD</u> vs. isolated colonic disease.</li><li>- FDA label recommends use <q>after TNF-antagonist failure</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- Use shared decision-making, considering patient factors (age, comorbidities, pregnancy plans, route of administration).</li><li>- <b>JAK inhibitors</b> (upadacitinib) should generally be <u>avoided</u> in women contemplating pregnancy due to limited safety data.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Advanced Therapy-Exposed Patients</b> (Rec 4)</strong></summary>
            <div>
                <ul><li>- Primarily applies to patients with prior <b>TNF antagonist</b> exposure.</li><li>- AGA <u>suggests</u> using a <b>HIGHER</b> or <b>INTERMEDIATE</b> efficacy medication over a <b>LOWER</b> efficacy medication.</li><li>- This is a <u>conditional recommendation</u> (low to moderate certainty evidence).</li></ul>
                
        <details>
            <summary><strong>Higher Efficacy Medications</strong></summary>
            <div>
                <ul><li>- <b>Adalimumab</b></li><li>- <b>Risankizumab</b></li><li>- <b>Guselkumab</b></li><li>- <b>Upadacitinib</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Intermediate Efficacy Medications</strong></summary>
            <div>
                <ul><li>- <b>Ustekinumab</b></li><li>- <b>Mirikizumab</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Lower Efficacy Medications</strong></summary>
            <div>
                <ul><li>- <b>Vedolizumab</b></li><li>- <b>Certolizumab pegol</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- Second-line TNF antagonists (e.g., adalimumab) may be effective if first TNF antagonist was stopped for <q>immunogenicity or intolerance</q>, but not for primary non-response.</li><li>- <b>JAK inhibitors</b> may have higher risk of MACE and cancer in older adults with cardiovascular risk factors.</li><li>- Avoid JAK inhibitors in women of childbearing age contemplating pregnancy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Use of Immunomodulators (Recs 5-8)</strong></summary>
            <div>
                <ul><li>- Covers thiopurines (azathioprine, mercaptopurine) and methotrexate as monotherapy.</li></ul>
                
        <details>
            <summary><strong>Thiopurines</strong></summary>
            <div>
                <ul><li>- AGA suggests <b>AGAINST</b> using thiopurine monotherapy for <u>inducing remission</u> (very low certainty).</li><li>- AGA <b>SUGGESTS</b> using thiopurine monotherapy for <u>maintaining remission</u> (low certainty), typically after corticosteroid induction.</li></ul>
                
        <details>
            <summary><strong>Dosing</strong></summary>
            <div>
                <ul><li>- <b>Azathioprine:</b> <q>2.0–2.5 mg/kg/d</q></li><li>- <b>Mercaptopurine:</b> <q>1.0–1.5 mg/kg/d</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Methotrexate (MTX)</strong></summary>
            <div>
                <ul><li>- AGA <b>SUGGESTS</b> using <u>subcutaneous or intramuscular</u> MTX monotherapy for induction and maintenance (moderate certainty).</li><li>- AGA suggests <b>AGAINST</b> using <u>oral</u> MTX monotherapy (very low certainty).</li></ul>
                
        <details>
            <summary><strong>Dosing</strong></summary>
            <div>
                <ul><li>- <b>Induction:</b> <q>25 mg weekly</q> for 16–24 weeks.</li><li>- <b>Maintenance:</b> <q>15 mg weekly</q>.</li><li>- Should be accompanied by daily folic acid supplementation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contraindication</strong></summary>
            <div>
                <ul><li>- Use of methotrexate is <u>contraindicated</u> in women actively considering pregnancy or who are pregnant.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring & Harms</strong></summary>
            <div>
                <ul><li>- Routine monitoring of <b>complete blood counts</b> and <b>liver function tests</b> is recommended for both thiopurines and methotrexate.</li><li>- Risks include bone marrow suppression, hepatotoxicity, infections, and nonmelanoma skin cancers.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Combination Therapy</strong></summary>
            <div>
                <ul><li>- Focuses on combining biologics with immunomodulators.</li></ul>
                
        <details>
            <summary><strong><b>TNF Antagonists + Immunomodulators</b> (Recs 9-11)</strong></summary>
            <div>
                <ul><li>- Evidence is mixed and depends on the specific agents and patient population.</li></ul>
                
        <details>
            <summary><strong>Infliximab + Thiopurines</strong></summary>
            <div>
                <ul><li>- In thiopurine-<b>NAÏVE</b> patients starting infliximab, AGA <b>SUGGESTS</b> using <u>combination therapy</u> over infliximab monotherapy (low certainty).</li><li>- Based on the <b>SONIC trial</b>, which showed higher remission rates with combination therapy.</li></ul>
                
        <details>
            <summary><strong>SONIC Trial Data</strong></summary>
            <div>
                <ul><li>- Sustained remission at 26 weeks: <q>Combination therapy was associated with higher rates (RR, 1.28)</q> compared to infliximab monotherapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Infliximab + Methotrexate</strong></summary>
            <div>
                <ul><li>- <b>NO RECOMMENDATION</b> due to knowledge gap.</li><li>- The <b>COMMIT trial</b> showed no significant difference between combination therapy and monotherapy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adalimumab + Thiopurines/Methotrexate</strong></summary>
            <div>
                <ul><li>- <b>NO RECOMMENDATION</b> due to knowledge gap.</li><li>- The <b>DIAMOND trial</b> (adalimumab + azathioprine) showed no difference in clinical remission, though endoscopic remission was higher at week 26.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- Benefit is <u>uncertain</u> in patients who have previously failed immunomodulator monotherapy.</li><li>- Combination therapy may be beneficial in patients at high risk for immunogenicity (e.g., history of immunogenicity, re-exposure after a lapse, <q><b>HLA-DQA1*05</b></q> carriers).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Non-TNF Biologics + Immunomodulators</b> (Rec 12)</strong></summary>
            <div>
                <ul><li>- Applies to vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab.</li><li>- <b>NO RECOMMENDATION</b> in favor of or against combination therapy due to a knowledge gap.</li><li>- Post-hoc analyses and observational studies show <u>no clear benefit</u>.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>- Non-TNF biologics appear to be <u>less immunogenic</u> than TNF antagonists.</li><li>- Concomitant immunomodulators do not seem to significantly alter their pharmacokinetic properties (e.g., trough concentrations).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>De-Escalation of Therapy (Recs 13 & 14)</strong></summary>
            <div>
                <ul><li>- For patients in corticosteroid-free clinical remission for at least <q><b>6 months</b></q> on combination therapy (TNF antagonist + immunomodulator).</li></ul>
                
        <details>
            <summary><strong><b>Withdraw the IMMUNOMODULATOR</b> (Conditional Rec)</strong></summary>
            <div>
                <ul><li>- AGA <b>SUGGESTS</b> withdrawing the immunomodulator.</li><li>- Meta-analysis showed <u>no significant difference</u> in relapse risk (16.8% with withdrawal vs. 14.9% continued combo).</li><li>- Rationale: Reduce long-term risks of immunomodulator (infection, malignancy).</li></ul>
                
        <details>
            <summary><strong>Consider Continuing Combo Therapy If:</strong></summary>
            <div>
                <ul><li>- Patient places high value on avoiding even a small risk of relapse.</li><li>- Patient is at high risk of immunogenicity (e.g., prior failure, low trough levels, <q>HLA-DQA1*05</q> carrier).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>AGAINST Withdrawing the TNF ANTAGONIST</b> (Conditional Rec)</strong></summary>
            <div>
                <ul><li>- AGA suggests <b>AGAINST</b> withdrawing the TNF antagonist.</li><li>- Meta-analysis showed a <u>significantly higher</u> risk of clinical relapse.</li><li>- Relapse rate: <q>30.6% with TNF antagonist withdrawal</q> vs. <q>11.2% with continued combo therapy</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Early Advanced Therapy (Rec 15)</strong></summary>
            <div>
                <ul><li>- Compares upfront use of advanced therapy vs. a step-up approach (corticosteroids/immunomodulators first).</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>- AGA <b>SUGGESTS</b> <u>upfront use of advanced therapy</u> over step-up therapy.</li><li>- This is a <u>conditional recommendation</u> based on very low certainty evidence.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence Summary</strong></summary>
            <div>
                <ul><li>- Meta-analysis of 3 RCTs showed the benefit for clinical remission at 12 months was uncertain.</li><li>- However, there was a trend towards a <u>lower risk of disease-related complications</u> (hospitalization, surgery, fistula, stricture) with early combination therapy.</li></ul>
                
        <details>
            <summary><strong>PROFILE Study Highlight</strong></summary>
            <div>
                <ul><li>- In newly diagnosed patients, early combo therapy led to significantly higher rates of steroid- and surgery-free remission (<q>79% vs 15%</q>) and endoscopic healing (<q>67% vs 44%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- All trials used combination therapy with a <b>TNF antagonist and an immunomodulator</b>.</li><li>- Corticosteroids may still be used for initial symptom management while initiating advanced therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treat-to-Target Strategies (Rec 16)</strong></summary>
            <div>
                <ul><li>- Compares treating to a target of endoscopic remission vs. symptomatic remission.</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>- <b>NO RECOMMENDATION</b> in favor of or against treating to a target of endoscopic remission.</li><li>- This is a <u>knowledge gap</u> due to very low certainty of evidence from available RCTs (STARDUST, REACT-2).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence Summary</strong></summary>
            <div>
                <ul><li>- The two available RCTs showed <b>no significant differences</b> in achieving clinical or endoscopic remission with a treat-to-endoscopic-target strategy vs. usual care/symptom-based strategy.</li><li>- There was significant heterogeneity between the trials in design and patient populations.</li></ul>
                
        <details>
            <summary><strong>Context & Rationale</strong></summary>
            <div>
                <ul><li>- While observational data suggest achieving endoscopic remission leads to better long-term outcomes, RCTs have not yet proven that an <u>algorithmic strategy</u> of treating toward this target improves outcomes over a symptom-based approach.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
